Tech Company Financing Transactions

bit.bio Funding Round

On 11/4/2026, bit.bio landed $25 million in Series D investment from private investors and M&G Investments.

Transaction Overview

Company Name
Announced On
11/4/2026
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds to expand its portfolio of human cell types, increase market availability, and support wider customer access.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
The Dorothy Hodgkin Building, Babraham Research Campus
Cambridge, CB22 3FH
UK
Email Address
Overview
bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting approach (opti-ox�; Pawlowski 2017) to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature human cell types. The company has expertise in the underpinning science of synthetic biology and stem cells, manufacturing, and clinical translation. The board is chaired by Lord David Prior.
Profile
bit.bio LinkedIn Company Profile
Social Media
bit.bio Company Twitter Account
Company News
bit.bio News
Facebook
bit.bio on Facebook
YouTube
bit.bio on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Emma Pepperell
  Emma Pepperell LinkedIn Profile  Emma Pepperell Twitter Account  Emma Pepperell News  Emma Pepperell on Facebook
Chief Financial Officer
Sam Jones
  Sam Jones LinkedIn Profile  Sam Jones Twitter Account  Sam Jones News  Sam Jones on Facebook
Chief Operating Officer
Adam Rowe
  Adam Rowe LinkedIn Profile  Adam Rowe Twitter Account  Adam Rowe News  Adam Rowe on Facebook
Chief Technical Officer
Sejla Salic-Hainzl
  Sejla Salic-Hainzl LinkedIn Profile  Sejla Salic-Hainzl Twitter Account  Sejla Salic-Hainzl News  Sejla Salic-Hainzl on Facebook
VP - Bus. Development
Niv Pande
  Niv Pande LinkedIn Profile  Niv Pande Twitter Account  Niv Pande News  Niv Pande on Facebook
VP - General Counsel
Kai Gan
  Kai Gan LinkedIn Profile  Kai Gan Twitter Account  Kai Gan News  Kai Gan on Facebook
VP - Human Resources
Vicki Bell
  Vicki Bell LinkedIn Profile  Vicki Bell Twitter Account  Vicki Bell News  Vicki Bell on Facebook
VP - Sales
Connie O'Donnell
  Connie O'Donnell LinkedIn Profile  Connie O'Donnell Twitter Account  Connie O'Donnell News  Connie O'Donnell on Facebook


 

 

Browse more venture capital transactions:

Prev: 11/4/2026: Sporta venture capital transaction
Next: 11/4/2026: Lazzaro One venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary